Vascular endothelial growth factor C - A potent risk factor in childhood acute lymphoblastic leukaemia: An immunocytochemical approach

Histopathology

Volumn 49, Issue 2, 2006, Pages 170-177

  Nowicki, M ^a   Ostalska Nowicka, D ^a   Kaczmarek, E ^a   Miskowiak, B ^a   Witt, M ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Acute lymphoblastic leukaemia; Prognosis; VEGF C

Indexed keywords

MONOCLONAL ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANALYTIC METHOD; ARTICLE; BLAST CELL; BONE MARROW; CANCER REGRESSION; CANCER RELAPSE; CARCINOGENESIS; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; FISHER EXACT TEST; HEMATOPOIETIC CELL; HUMAN; IMMUNOCYTOCHEMISTRY; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 33746065362     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02465.x     Document Type: Article

References (48)

1. Brown LF, Detmar M, Claffey K et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In Goldberg ID, Rosen EM eds. Regulation of angiogenesis. Basel: Birkhauser-Verlag 1997; 233-269.
2. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc. Res. 2005; 65; 550-563.
3. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J. Anat. 2002; 200; 581-597.
4. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein and NO production in human endothelial cells. Am. J. Physiol. 1998; 274; H1054-H1058.
5. Kroll J, Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem. Biophys. Res. Commun. 1999; 265; 636-699.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003; 9; 669-676.
7. Storkebaum E, Lambrechts D, Carmeliet P. VEGF; once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26; 943-954.
8. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999; 59; 728-733.
9. Ratajczak MZ, Ratajczak J, Machalinski B et al. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth. Br. J. Haematol. 1998; 103; 969-979.
10. Joukov V, Pajusola K, Kaipainen A et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and Kdr (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996; 15; 290-298.
11. Kukk E, Lymboussaki A, Taira S et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122; 3829-3837.
12. Cao Y, Linden P, Farnebo J et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl Acad. Sci. USA 1998; 95; 14389-14394.
13. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl Acad. Sci. USA 1996; 93; 1988-1992.
14. Ostalska-Nowicka D, Zachwieja J, Nowicki M, Kaczmarek E, Siwiñska A, Witt M. Vascular endothelial growth factor (VEGF-C1)-dependent inflammatory response of podocytes in nephrotic syndrome glomerulopathies in children: an immunohistochemical approach. Histopathology 2005; 46; 176-183.
15. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 2004; 25; 387-395.
16. Skobe M, Hawighorst T, Jackson DG et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001; 7; 192-198.
17. Karpen T, Alitalo K. Lymphatic vessels as targets of tumor therapy? J. Exp. Med. 2001; 194; F37-F42.
18. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem. 1998; 273; 8413-8418.
19. Yonekura H, Sakurai S, Liu X et al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J. Biol. Chem. 1999; 274; 35172-35178.
20. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407; 249-257.
21. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285; 1182-1186.
22. Folkman J. Clinical applications of research on angiogenesis. N. Engl. J. Med. 1995; 333; 1757-1763.
23. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit. Rev. Oncol. Hematol. 2003; 45; 227-244.
24. Aguayo A, O'Brien S, Keating M et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000; 96; 768-770.
25. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 1997; 150; 815-821.
26. Koomagi R, Zintl F, Sauerbrey A, Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin. Cancer Res. 2001; 7; 3381-3384.
27. Riehm H. Multizentrische Therapiestudie ALL-BFM 90 zur Behandlung von Kindern und Jugendlichen mit akuter lymphoblastischer Leukämie (Non-B-ALL). Hannover: Therapieprotokoll 1991.
28. Steinherz PG, Gaynon PS, Miller DR et al. Improved disease-free survival of children with acute lymphoblastic leukaemia at high risk for early relapse with New York regimen - a new intensive therapy protocol: a report from the Children's Cancer Study Group. J. Clin. Oncol. 1986; 4; 744-752.
29. Henze G, Fengler R, Adams HP. ALL-REZ BFM 96 - Studie zur Behandlung von Kindern mit Rezidivi einer akuten lymphoblastischen Leukämie. Berlin: Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) 1997.
30. Pillai G, Cook N, Turley H et al. The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study. Histopathology 2005; 46; 209-216.
31. Partanen TA, Arola J, Saaristo A et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 2000; 14; 2087-2096.
32. Armitage P. Statistical methods in medical investigations, 1st edn (in Polish). Warsaw: PZWL 1978; 97-103.
33. Aguayo A, Estey E, Kantarjian H et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94; 3717-3721.
34. Dankbar B, Padro T, Leo R et al. Vascular endothelial growth factor and interleukine-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95; 2630-2636.
35. Foss HD, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman disease. J. Pathol. 1997; 183; 44-50.
36. Dias S, Choy M, Alitalo K, Rafii S. Vasacular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediated leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002; 99; 2179-2184.
37. de Bont ESJM, Neefjes VME, Rosati S, Vellenga E, Kamps WA. New vessel formation and aberrant VEGF/VEGFR signaling in acute leukemia: does it matter? Leuk. Lymphoma 2002; 43; 1901-1909.
38. Dias S, Hattori K, Zhu Z et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 2000; 106; 511-521.
39. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 2001; 112; 1-17.
40. Stacker SA, Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001; 7; 186-191.
41. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett. 1995; 370; 203-208.
42. Kaipainen A, Korhonen J, Mustonen T et al. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to endothelium of lymphatic vessels during development. Proc. Natl Acad. Sci. USA 1995; 92; 3566-3570.
43. Achen MG, Jeltsch M, Kukk E et al. Vascular endothelial growth factor D, VEGF-D, is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Prof. Natl Acad. Sci. USA 1998; 95; 548-553.
44. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999; 86; 2406-2412.
45. Skobe M, Hamberg LM, Hawighorst T et al. Concurrent induction of lymphangiogenesis, angiogenesis and macrophage recruitment by VEGF-C in melanoma. Am. J. Pathol. 2001; 159; 893-903.
46. Fiedler W, Graeven U, Ergün S et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89; 1870-1875.
47. Katoh O, Takahashi T, Oguri T et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res. 1999; 19; 3399-3402.
48. Ghannadan M, Wimazal F, Simonitsch I et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correletion between VEGF expression and the FAB category. Am. J. Clin. Pathol. 2003; 119; 663-671.